Franz Buchegger

Title: Franz Buchegger: Innovator in Monoclonal Antibodies

Introduction

Franz Buchegger is a notable inventor based in Chexbres, Switzerland. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. His work has implications for cancer diagnosis and therapy, showcasing the importance of innovation in medical science.

Latest Patents

Franz Buchegger holds a patent for "Monoclonal antibodies with specificity affinity for human." This invention involves novel monoclonal antibodies that exhibit high specificity and affinity for human carcinoembryonic antigen (CEA). The patent details processes for preparing these antibodies and their derivatives, as well as hybridoma cell lines that secrete the antibodies. These monoclonal antibodies are crucial for diagnosing cancer and monitoring patients for recurrent disease or response to therapy. Additionally, the invention includes test kits and pharmaceutical compositions containing these monoclonal anti-CEA antibodies.

Career Highlights

Franz Buchegger has been associated with Research Corporation Technologies, Inc., where he has furthered his research and development efforts. His work has been instrumental in advancing the understanding and application of monoclonal antibodies in clinical settings.

Collaborations

Franz has collaborated with Jean-Pierre Mach, a fellow researcher, to enhance the development and application of their innovative technologies. Their partnership has contributed to the success of their projects and the advancement of cancer treatment methodologies.

Conclusion

Franz Buchegger's contributions to the field of monoclonal antibodies represent a significant advancement in cancer diagnosis and therapy. His innovative work continues to impact the medical community positively.